Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
Saved in:
| Title: | Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age. |
|---|---|
| Authors: | Poder A; Tartu University Hospital, 50406 Tartu, Estonia., Oberije J; CSL Seqirus, 1105 BJ Amsterdam, The Netherlands., Meyer J; Velocity Clinical Research, Lincoln, NE 68510, USA., Heymer P; Klinische Forschung Dresden GmbH, 01069 Dresden, Germany., Molrine D; CSL Seqirus, Waltham, MA 02451, USA., Versage E; CSL Seqirus, Waltham, MA 02451, USA., Isakov L; CSL Seqirus, Waltham, MA 02451, USA., Zhang Q; CSL Seqirus, Summit, NJ 07901, USA., Hohenboken M; CSL Seqirus, Waltham, MA 02451, USA. |
| Source: | Vaccines [Vaccines (Basel)] 2023 Sep 26; Vol. 11 (10). Date of Electronic Publication: 2023 Sep 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
